{"prompt": "['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '11', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'Section # and Name', 'Description of Change', 'Brief Rationale', '9 Statistical Analysis Plan', 'Added notes to clarify that the study has', 'In accordance with the reduced scope of the study and', '9.1 Statistical Analysis Plan', 'been unblinded, enrollment in the', 'discontinuation of efficacy data collection.', 'Summary', 'Extension Study in China has been', 'stopped, and no further prespecified', '9.5 Analysis Populations', 'analysis of primary, secondary, and', 'exploratory endpoints will be performed.', 'Subsections updated accordingly.', '9.2 Responsibility for', 'Added note to clarify that the study has', 'Analyses/In-house Blinding', 'been unblinded. Updated content to reflect', 'the current status of the trial with regards', 'to blinding.', '9.6 Statistical Methods', 'Added note to clarify that the selected', 'analyses of safety and ePRO endpoints', 'will be performed at end of study, and', 'there will be no further analyses of', 'efficacy endpoints. Sections have been', 'retained for reference.', '9.7 Interim Analyses', 'Removed content and added notes to', '9.8 Multiplicity', 'clarify that no interim or final analyses of', 'the study will be performed and sections', '9.9 Sample Size and Power', 'are no longer applicable.', 'Calculations', '10.7.3 Canada-specific', 'Section updated to remove lenvatinib', 'Lenvatinib has been removed from the study.', 'Requirements', 'references.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'Confidential']['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '12', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'Section # and Name', 'Description of Change', 'Brief Rationale', 'Throughout', 'All references to lenvatinib and placebo', 'In accordance with the overall rationale for the', 'were removed. Where deletion of text', 'amendment.', 'could cause confusion due to the original', 'design of the study or where text is useful', 'to understand the overall context of the', 'study, the text has been left unchanged and', 'a note was added. Added clarifying notes', 'regarding removal of lenvatinib and', 'matching placebo from the study.', 'Made typographical corrections and minor', 'To correct typographical errors and clarify intended', 'administrative edits.', 'meaning.', 'ADDITIONAL CHANGE(S) FOR THIS AMENDMENT:', 'No additional changes.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'Confidential']['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '13', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'Table of Contents', 'DOCUMENT HISTORY', '3', 'PROTOCOL AMENDMENT SUMMARY OF CHANGES', '5', '1', 'PROTOCOL SUMMARY', '22', '1.1', 'Synopsis', '22', '1.2', 'Schema', '28', '1.3', 'Schedule of Activities (SoA)', '29', '1.3.1', 'Initial Treatment Phase', '29', '1.3.2', 'Second-course Treatment Phase', '40', '2', 'INTRODUCTION', '41', '2.1', 'Study Rationale', '41', '2.2', 'Background', '43', '2.2.1', 'Pharmaceutical and Therapeutic Background', '43', '2.2.1.1', 'Lenvatinib', '43', '2.2.1.2', 'Pembrolizumab', '44', '2.2.1.3', 'Pembrolizumab With Lenvatinib', '44', '2.2.2', 'Preclinical and Clinical Studies', '45', '2.2.2.1', 'Completed Studies With Pembrolizumab and Lenvatinib', '45', '2.2.3', 'Ongoing Clinical Studies of Pembrolizumab and Lenvatinib', '45', '2.3', 'Benefit/Risk Assessment', '46', '3', 'HYPOTHESES, OBJECTIVES, AND ENDPOINTS', '46', '4', 'STUDY DESIGN', '50', '4.1', 'Overall Design', '50', '4.2', 'Scientific Rationale for Study Design', '51', '4.2.1', 'Rationale for Endpoints', '51', '4.2.1.1', 'Efficacy Endpoints', '51', '4.2.1.1.1', 'RECIST 1.1', '52', '4.2.1.1.2', 'Adjusted RECIST 1.1 for Immune-based Therapeutics', 'iRECIST', '52', '4.2.1.2', 'Safety Endpoints', '52', '4.2.1.3', 'Patient-reported Outcomes', '53', '4.2.1.3.1', 'EORTC QLQ-C30', '53', '4.2.1.3.2', 'EORTC QLQ-LC13', '53', '4.2.1.3.3', 'EuroQoL EQ-5D-5L', '53', '4.2.1.4', 'Pharmacokinetic Endpoints', '54', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']\n\n###\n\n", "completion": "END"}